Shares of Shire PLC (LON:SHP) have been assigned an average rating of “Buy” from the nineteen research firms that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 4,937.50 ($68.22).
Several research firms recently issued reports on SHP. Liberum Capital restated a “hold” rating and set a GBX 4,000 ($55.26) price target on shares of Shire in a research report on Wednesday, March 7th. Credit Suisse Group restated an “outperform” rating and set a GBX 4,000 ($55.26) price target on shares of Shire in a research report on Monday, March 5th. Societe Generale reduced their price target on Shire from GBX 8,000 ($110.53) to GBX 7,500 ($103.62) and set a “buy” rating on the stock in a research report on Wednesday, February 28th. Shore Capital restated a “buy” rating on shares of Shire in a research report on Friday, February 23rd. Finally, Berenberg Bank reduced their price target on Shire from GBX 6,000 ($82.90) to GBX 4,500 ($62.17) and set a “buy” rating on the stock in a research report on Friday, February 23rd.
Shire (LON:SHP) traded down GBX 13.50 ($0.19) on Wednesday, reaching GBX 3,179 ($43.92). The company had a trading volume of 1,456,111 shares, compared to its average volume of 3,180,000. Shire has a fifty-two week low of GBX 2,940.50 ($40.63) and a fifty-two week high of GBX 5,021 ($69.37). The company has a market cap of $28,950.00 and a price-to-earnings ratio of 2,177.40.
In other Shire news, insider Dominic Blakemore acquired 165 shares of the business’s stock in a transaction dated Tuesday, December 19th. The shares were purchased at an average cost of GBX 3,790 ($52.36) per share, for a total transaction of £6,253.50 ($8,639.82).
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/03/12/shire-plc-shp-receives-gbx-4937-50-consensus-target-price-from-analysts.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.